Assistant Professor, Internal Medicine, University of Texas Southwestern Medical Center, Southwestern Medical School
Hematology
Dr. Nima Sharifi, MD
|
|
Give Review
Nima Sharifi is an expert in the field of Hematology. He attended University of Pittsburgh School of Medicine. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Nima Sharifi, MD is a published physician. He has 43 papers published. The most current publication "Androstenedione is the preferred androgen source in hormone refractory prostate cancer-letter."
Publications
- Androstenedione is the preferred androgen source in hormone refractory prostate Cancer-letter.
- The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate Cancer growth.
- Androgen metabolism in prostate Cancer: from molecular mechanisms to clinical consequences.
- Mechanisms of androgen receptor activation in castration-resistant prostate Cancer.
- A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer.
- The role of DAB2IP in androgen receptor activation during prostate Cancer progression.
- Prostate Cancer-from steroid transformations to clinical translation.
- Isolation and characterization of the mouse homolog of the preprodynorphin (Pdyn) gene.
- Generation of dynorphin knockout mice.
- SOD mimetics: a novel class of androgen receptor inhibitors that suppresses castration-resistant growth of prostate Cancer.
- The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate Cancer.
- Clinical implications of the 5α-androstanedione pathway for castration-resistant prostate Cancer.
- Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate Cancer.
- SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer.
- "Getting from here to there"--mechanisms and limitations to the activation of the androgen receptor in castration-resistant prostate Cancer.
- Survivin is not induced by novel taxanes.
- An update on androgen deprivation therapy for prostate Cancer.
- 3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate Cancer.
- New agents and strategies for the hormonal treatment of castration-resistant prostate Cancer.
- More than an accessory: implications of type III transforming growth factor-beta receptor loss in prostate Cancer.
- Hormonal therapy for prostate Cancer: toward further unraveling of androgen receptor function.
- Commentary: Antioxidants for Cancer: new tricks for an old dog?
- Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate Cancer.
- The genetics of castration-resistant prostate Cancer: what can the germline tell us?
- A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate Cancer.
- Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic Cancer.
- Re: "Body size, weight cycling, and risk of renal cell carcinoma among postmenopausal women: the women's health initiative (United States)".
- Androgen receptor expression in prostate Cancer stem cells: is there a conundrum?
- Transforming growth factor-beta receptor III downregulation in prostate Cancer: is inhibin B a tumor suppressor in prostate?
- Secondary hormonal therapy for prostate Cancer: what lies on the horizon?
- Androgen receptor modulation: lessons learned from beyond the Prostate.
- Screening for prostate Cancer: current status and future prospects.
- A bifunctional colchicinoid that binds to the androgen receptor.
- TGFBR3 loss and consequences in prostate Cancer.
- Stem cells in prostate Cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy.
- Androgen receptor as a therapeutic target for androgen independent prostate Cancer.
- Perturbations in hypoxia detection: a shared link between hereditary and sporadic tumor formation?
- A retrospective study of the time to clinical endpoints for advanced prostate Cancer.
- Androgen deprivation therapy for prostate Cancer.
- Vascular events after acute infection or vaccination.
- Gene function far from understood.
- Targeted chemotherapy: chronic myelogenous leukemia as a model.
Schools
University of Pittsburgh Main Campus
Conditions Treated
- Anemia
- Bladder Cancer
- Colorectal Cancer
- Liver Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
National Institutes of Health Clinical Center -
Yale-New Haven Hospital -
University of Pittsburgh School of Medicine
Hospital
-
University of Texas Southwestern Medical Center -
Cleveland Clinic
Helpful Reviews
Similar Doctors
|
|
Dr. Joseph W. Fay, MD |
|
|
Dr. Cheryl A. Harth, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carlos Taboada, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Barry Cooper, MD |
|
|
Dr. Mateel S. Graham, MD |
|
|
Dr. Roy S. Paulson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Luis A. Pineiro, MD |
|
|
Dr. Jiu Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cesar A. Santa-Maria, MD |
|
|
Dr. Charles C. Cunningham, MD
This Doctor is OpenDoctor Recommended.
|